Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Lichtenstein

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
International Journal of Cancer|June 23, 2010
IL-2-granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3-independent apoptotic pathwayInna Grodzovski, Michal Lichtenstein, Hanan Galski, et al.
Molecular Medicine (Cambridge, Mass.)|May 15, 2013
Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cellsDana Marcus, Michal Lichtenstein, Ann Saada, et al.
Biotechnology Progress|January 26, 2012
Eliminating the six N-terminal amino acids of the caspase 3 large subunit improved production of a biologically active IL2-Caspase3 chimeric proteinYitav Glantz, Ofra Sabag, Michal Lichtenstein, et al.
International Immunopharmacology|July 28, 2009
IL2-caspase3 chimeric protein controls lymphocyte reactivity by targeted apoptosis, leading to amelioration of experimental autoimmune encephalomyelitisMichal Irony-Tur-Sinai, Michal Lichtenstein, Talma Brenner, et al.
International Journal of Molecular Sciences|May 14, 2025
Rescue of the First Mitochondrial Membrane Carrier, the mPiC, by TAT-Mediated Protein Replacement TreatmentSamar Zabit, Orly Melloul, Michal Lichtenstein, et al.
Cancers|April 14, 2025
Inducing Targeted, Caspase-Independent Apoptosis with New Chimeric Proteins for Treatment of Solid CancersOrly Melloul, Samar Zabit, Michal Lichtenstein, et al.
Thescientificworldjournal|December 6, 2014
Evaluating medicinal plants for anticancer activityElisha Solowey, Michal Lichtenstein, Sarah Sallon, et al.
Cancers|January 8, 2023
Exploiting the Endogenous Ubiquitin Proteasome System in Targeted Cancer TreatmentNoa Hauser, Joud Hirbawi, Meshi Saban Golub, et al.
Life (Basel, Switzerland)|September 28, 2021
TAT for Enzyme/Protein Delivery to Restore or Destroy Cell Activity in Human DiseasesMichal Lichtenstein, Samar Zabit, Noa Hauser, et al.
The International Journal of Biochemistry & Cell Biology|November 6, 2016
Heterologous mitochondrial targeting sequences can deliver functional proteins into mitochondriaDana Marcus, Michal Lichtenstein, Natali Cohen, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
International Journal of Cancer|June 23, 2010
IL-2-granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3-independent apoptotic pathwayInna Grodzovski, Michal Lichtenstein, Hanan Galski, et al.
Molecular Medicine (Cambridge, Mass.)|May 15, 2013
Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cellsDana Marcus, Michal Lichtenstein, Ann Saada, et al.
Biotechnology Progress|January 26, 2012
Eliminating the six N-terminal amino acids of the caspase 3 large subunit improved production of a biologically active IL2-Caspase3 chimeric proteinYitav Glantz, Ofra Sabag, Michal Lichtenstein, et al.
International Immunopharmacology|July 28, 2009
IL2-caspase3 chimeric protein controls lymphocyte reactivity by targeted apoptosis, leading to amelioration of experimental autoimmune encephalomyelitisMichal Irony-Tur-Sinai, Michal Lichtenstein, Talma Brenner, et al.
International Journal of Molecular Sciences|May 14, 2025
Rescue of the First Mitochondrial Membrane Carrier, the mPiC, by TAT-Mediated Protein Replacement TreatmentSamar Zabit, Orly Melloul, Michal Lichtenstein, et al.
Cancers|April 14, 2025
Inducing Targeted, Caspase-Independent Apoptosis with New Chimeric Proteins for Treatment of Solid CancersOrly Melloul, Samar Zabit, Michal Lichtenstein, et al.
Thescientificworldjournal|December 6, 2014
Evaluating medicinal plants for anticancer activityElisha Solowey, Michal Lichtenstein, Sarah Sallon, et al.
Cancers|January 8, 2023
Exploiting the Endogenous Ubiquitin Proteasome System in Targeted Cancer TreatmentNoa Hauser, Joud Hirbawi, Meshi Saban Golub, et al.
Life (Basel, Switzerland)|September 28, 2021
TAT for Enzyme/Protein Delivery to Restore or Destroy Cell Activity in Human DiseasesMichal Lichtenstein, Samar Zabit, Noa Hauser, et al.
The International Journal of Biochemistry & Cell Biology|November 6, 2016
Heterologous mitochondrial targeting sequences can deliver functional proteins into mitochondriaDana Marcus, Michal Lichtenstein, Natali Cohen, et al.
Pageof 3